NO983946L - Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner - Google Patents

Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Info

Publication number
NO983946L
NO983946L NO983946A NO983946A NO983946L NO 983946 L NO983946 L NO 983946L NO 983946 A NO983946 A NO 983946A NO 983946 A NO983946 A NO 983946A NO 983946 L NO983946 L NO 983946L
Authority
NO
Norway
Prior art keywords
vaccines
preparation
foreign dna
containing foreign
viruses containing
Prior art date
Application number
NO983946A
Other languages
English (en)
Norwegian (no)
Other versions
NO983946D0 (no
Inventor
Norbert Schmeer
Walter Strube
Ttner Mathias B
Hans-Joachim Rziha
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19639601A external-priority patent/DE19639601A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO983946D0 publication Critical patent/NO983946D0/no
Publication of NO983946L publication Critical patent/NO983946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO983946A 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner NO983946L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607458 1996-02-28
DE19639601A DE19639601A1 (de) 1996-02-28 1996-09-26 Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PCT/EP1997/000729 WO1997032029A1 (de) 1996-02-28 1997-02-17 Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen

Publications (2)

Publication Number Publication Date
NO983946D0 NO983946D0 (no) 1998-08-27
NO983946L true NO983946L (no) 1998-10-22

Family

ID=26023280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983946A NO983946L (no) 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Country Status (19)

Country Link
US (1) US6365393B1 (da)
EP (1) EP0886679B1 (da)
JP (1) JP2000507092A (da)
CN (1) CN1217027A (da)
AT (1) ATE364090T1 (da)
AU (1) AU718141B2 (da)
BR (1) BR9707785A (da)
CA (1) CA2247336C (da)
DE (1) DE59712852D1 (da)
DK (1) DK0886679T3 (da)
ES (1) ES2287949T3 (da)
HU (1) HUP9901035A3 (da)
IL (1) IL125797A0 (da)
NO (1) NO983946L (da)
NZ (1) NZ331556A (da)
PL (1) PL190401B1 (da)
SK (1) SK120098A3 (da)
TR (1) TR199801702T2 (da)
WO (1) WO1997032029A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708401A (pt) * 1996-03-29 2000-01-04 Univ Otago Vetores de vìrus de para-varìola
DE69939374D1 (de) * 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
EP1126863B1 (en) * 1998-11-02 2006-05-03 Ludwig Institute For Cancer Research Vascular endothelial growth factor-like protein from orf virus nz10 binds and activates mammalian vegf receptor-2
LU90997B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals ans anticancer pharmaceuticals
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
CN1984666A (zh) * 2004-07-13 2007-06-20 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
KR20130058706A (ko) 2010-04-29 2013-06-04 림사 아르쯔나이미텔 아게 토끼 출혈병 바이러스의 ｖｐ６０ 주요 캡시드 단백질을 발현하는 파라폭스바이러스
EP2571521A1 (en) * 2010-05-21 2013-03-27 Ah Usa 42 Llc Parapoxvirus vectors containing rabies virus antigen
WO2012011045A1 (en) * 2010-07-20 2012-01-26 Pfizer Inc. Parapoxvirus vectors
MX2015000789A (es) 2012-07-19 2015-05-07 Zoetis Llc Composiciones de virus de la gripe bovina.
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN115141772A (zh) 2015-08-14 2022-10-04 硕腾服务有限责任公司 牛支原体组合物
EP3432922B1 (en) 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
MX2020009262A (es) * 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU694519B2 (en) * 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions

Also Published As

Publication number Publication date
DE59712852D1 (de) 2007-07-19
BR9707785A (pt) 1999-07-27
TR199801702T2 (xx) 1998-12-21
AU1725797A (en) 1997-09-16
NZ331556A (en) 2000-05-26
PL190401B1 (pl) 2005-12-30
US6365393B1 (en) 2002-04-02
PL328870A1 (en) 1999-03-01
IL125797A0 (en) 1999-04-11
CA2247336A1 (en) 1997-09-04
ATE364090T1 (de) 2007-06-15
CN1217027A (zh) 1999-05-19
JP2000507092A (ja) 2000-06-13
AU718141B2 (en) 2000-04-06
WO1997032029A1 (de) 1997-09-04
ES2287949T3 (es) 2007-12-16
DK0886679T3 (da) 2007-09-24
NO983946D0 (no) 1998-08-27
CA2247336C (en) 2008-06-17
HUP9901035A2 (hu) 1999-07-28
EP0886679B1 (de) 2007-06-06
EP0886679A1 (de) 1998-12-30
SK120098A3 (en) 1999-03-12
HUP9901035A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
ATE468858T1 (de) Chimäre impfstoffe gegen flaviviren
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
NO20013701L (no) HER-2/neu-fusjonsproteiner
HK1022719A1 (en) Hamster ef-1 alpha transcriptional regulatory DNA
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE328068T1 (de) Papillomavirus vakzine
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
IL181695A0 (en) Methods for cultivating cells and propagating viruses
YU36698A (sh) Parapoks-virusi koji sadrže stranu dnk, njihovo dobijanje i njihova primena u vakcinama
ATE346931T1 (de) Clostridium perfringens impfstoff
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application